6Sharms SK,Balamurugan A,Saha PK.et al.Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment[J].Am J Respir Crit Care Med,2002,166(7):916-919.
7Teleman MD,Chee CBE,Earnest A.et al.Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore[J].Int Tuberc Lung Dis,2002,6(8):699-705.
8American Thoracic Society/Centers For Disease Control and Prevention (ATS/CDC).Executive Committee,Update:Fatal and Severe Liver Injuries Associated With Rifampin and Pyrazinamide for Latent Tuberculosis Infection,and Revisions in American Thoracic Society/CDC Recommendations-United States,2001[J].Am J Respir Crit Care Med,2001,164(7):1319-1320.
9Nolan CM,Goldberg SV,Buskin SE.Hepatotoxicity associated with isoniazid prevention therapy[J].JAMA,1999,281:1014-1018.
10Ungo JR,Jones DA,shkin D.et al.Antituberculosis drug-induced hepatotoxicity the role of hepatitis C virus and the human immunodeficiency virus[J].Am J Respir Crit Care Med,1998,157(7):1871-1876.
10Marinker M, Sharp M. From compliance to concordance: Achieving shared goals in medicine taking[M]. London: Royal Pharmaceutical Soicety of Great Britain and Merck Sharp & Dohme,1997:1.
